Target intelligence / Profile preview

Glutamate receptor ionotropic, NMDA 3B (GRIN3B)

Target
GRIN3B
Molecular classification
Ion channel, Receptor, Ligand-gated ion channel, Neurotransmitter receptor
01

Overview

Glutamate receptor ionotropic, NMDA 3B (GRIN3B, also known as GluN3B or NR3B), is a subunit of the NMDA (N-methyl-D-aspartate) receptor, a type of ionotropic glutamate receptor that forms ligand-gated ion channels in the central nervous system. NMDA receptors are heterotetrameric complexes assembled from NR1, NR2 (A-D), and NR3 (A-B) subunits; GRIN3B encodes the GluN3B subunit. When incorporated, GluN3B changes the receptor’s electrophysiological properties—lowering calcium permeability and modifying channel activation and deactivation kinetics. GluN3B is expressed primarily in motor neurons and forms glycine-activated channels with GluN1 and glutamate-activated channels with GluN1 and GluN2. The NMDA receptor is critical for excitatory neurotransmission, synaptic plasticity, learning, and memory. Variants in GRIN3B have been associated with certain neurodevelopmental and neuropsychiatric disorders, though drugs specifically targeting this subunit are not currently available. NMDA receptor antagonists (like memantine and ketamine) act broadly on all NMDA receptor subunits

Other names
GluN3BNR3BNMDAR3BNMDA receptor subunit 3Bglutamate [NMDA] receptor subunit 3BN-methyl-D-aspartate receptor subtype 3Bglutamate ionotropic receptor NMDA type subunit 3BNMDA type glutamate receptor subunit NR3B
02

Mechanism of action

Channel blockade (voltage-dependent block by Mg2+ ions is reduced in GluN3B-containing NMDA receptors) - Inhibition of cation (Na+, K+, Ca2+) flux through the ion channel

03

Biological functions

Signal transductionSynaptic transmissionCalcium ion transportNeuroplasticityExcitatory neurotransmissionLearning and memory
04

Disease associations

EpilepsyDepersonalization disorderSchizophrenia (association proposed)Intellectual disability (as part of GRIN disorders)
05

Safety considerations

Potential risk of cognitive and psychiatric side effects (from non-specific NMDA receptor antagonism)Risk of neurotoxicity or altered synaptic plasticity with excessive blockade or activation
06

Interacting drugs

Memantine (non-specific NMDA receptor antagonist—no evidence for GRIN3B specificity, but acts on NMDA receptors in general)

1 more in the full profile.

07

Biomarkers

Variants in GRIN3B for some neurodevelopmental disorders (e.g., intellectual disability, epilepsy), but not established as clinical biomarkers

Beyond the preview

Go deeper on Glutamate receptor ionotropic, NMDA 3B (GRIN3B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate receptor ionotropic, NMDA 3B (GRIN3B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call